Highest-materiality recent filing
Verrica Q1 2026: Net revenue $5.0M; YCANTH units up 51% YoY; net loss $9.7M
YCANTH dispensed units 15,302 (+12.1% QoQ, +51.3% YoY); net product revenue $4.3M (+16.2% QoQ, +25.4% YoY).
Verrica Q4 2025: YCANTH net revenue up 130% to $15.3M; total revenue $35.6M
Q4 product revenue $3.7M vs $0.3M YoY; total revenue $35.6M in 2025, up from $7.6M in 2024.
Verrica raises ~$50M in PIPE to retire OrbiMed debt, extend runway into mid-2027
Gross proceeds of ~$50M from sale of 6.5M shares, 5.3M pre-funded warrants, and 2.95M Series C warrants.
Verrica Q3 revenue $14.3M (YCANTH $3.6M, license $10.7M); net loss narrows to $0.3M
Q3 net loss $0.3M ($0.03/sh) vs $22.9M loss ($4.88/sh) in Q3'24; non-GAAP net income $1.2M.
Verrica Q2 net income $0.2M; YCANTH units +32.8% QoQ; Nasdaq compliance regained
Q2 product revenue $4.5M; license & collaboration revenue $8.2M (incl. $8.0M Torii milestone). Net income $0.2M ($0.02 GAAP EPS) vs net loss $17.2M YoY.
Nasdaq Staff Determination issued July 24, 2025; company may request hearing to stay delisting.
Verrica Pharmaceuticals Announces 1-for-10 Reverse Stock Split Effective July 24, 2025
Verrica Pharmaceuticals (VRCA) filed a Certificate of Amendment to effect a 1-for-10 reverse stock split, authorized by stockholders on June 5, 2025.
Verrica amends Torii deal: $8M milestone accelerated, $10M on Japan approval, $40M trial funding
Torii pays $8M milestone in July 2025 for starting global Phase 3 common warts trial of YCANTH.
Verrica amends credit agreement, waives going concern covenant through Dec 2025
Sixth amendment waives Section 7.1(b) and 7.1(c) going concern qualifications for Q2'25, Q3'25, and FY2025 financial statements.
Verrica Q1 2025: YCANTH revenue $3.4M; dispensed 10,102 units (+16.7% QoQ)
Net loss $9.7M ($0.10/share) vs. $20.3M ($0.44) in Q1 2024; non-GAAP net loss $7.8M.
Verrica Q4 product revenue $0.3M, net loss $0.24/sh; YCANTH units up 12.3% sequentially
Q4 product revenue $0.3M (vs $1.9M in 2023); FY product revenue $6.6M (vs $4.7M) with $3.2M returns reserve.
Verrica enters lender waiver of going concern covenants for FY2024, Q1 2025
Lenders waive covenant requiring no going concern qualification in Dec 2024 and Mar 2025 financials.
Nasdaq notified Verrica on Jan 24, 2025 that bid price closed below $1.00 for 30 consecutive days, violating Listing Rule 5450(a)(1).
Verrica appoints David Zawitz as COO effective Dec 9; grants 950,000 option shares
David Zawitz appointed Chief Operating Officer and principal operating officer, effective Dec 9, 2024.
Verrica prices $42M public offering of common stock and warrants at $0.89/unit
Raised ~$42M gross from 44.96M common shares, 2.24M pre-funded warrants, and 47.2M Series A/B warrants at $0.89/unit.
Verrica launches underwritten public offering of common stock and warrants
Offering of common stock (or pre-funded warrants) and accompanying warrants; Jefferies sole bookrunner; 30-day option for 15% additional.
Verrica Q3 net product revenue negative $1.9M; CEO Ted White resigns, replaced by Dr. Rieger
Negative net product revenue of $1.9M in Q3 2024, including $1.7M provision for returns; no ex-factory sales.
Verrica out of Nasdaq compliance after director resignation; cure period granted
Craig Ballaron resigned from Board effective October 2, 2024.
Verrica cuts 47 jobs, expects $1.0M restructuring charge
Workforce reduction of 47 employees, substantially completed by October 1, 2024.
Verrica CFO Terence Kohler resigns effective Oct 4, 2024
CFO Terence Kohler notified company of resignation on Sep 23, 2024.
Verrica CCO Joe Bonaccorso resigns effective Aug 30, 2024; consulting role through Aug 2025
Joe Bonaccorso resigns as Chief Commercial Officer effective August 30, 2024.
Verrica Q2 2024: YCANTH revenue $4.9M; net loss $17.2M; positive Phase 2 BCC data
Net product revenue of $4.9M from YCANTH; net loss $17.2M ($0.37/sh) vs $11.0M ($0.24/sh) in Q2 2023.
Verrica amends credit deal with OrbiMed; revenue test delayed, exit fee hiked, going concern waived
Revenue test under Credit Agreement now begins December 31, 2024, instead of earlier date.
Amendment equally splits cost of global Phase 3 trial of YCANTH for common warts; Torii funds upfront, Verrica repays half with interest (SOFR+2% min 6%).
Verrica Q1 2024: YCANTH revenue $3.2M, net loss $20.3M, cash runway into Q1 2025
YCANTH product revenue of $3.2M; no prior-year comparable as sales began Q3 2023.
Verrica Q4 2023 YCANTH revenue $1.9M; net loss $24.6M vs $5.9M prior year
Full-year 2023 YCANTH product revenue $4.7M; first commercial revenue after Q3 2023 launch.
Verrica posts Q3 2023 net loss of $24.8M; first YCANTH revenue $2.8M
First commercial YCANTH sale to distributor FFF generated $2.8M product revenue; net loss $24.8M ($0.54/share).
Verrica FDA approval of YCANTH for molluscum and Q2 net loss $11M; cash runway to Q1 2025
FDA approved YCANTH (cantharidin) on July 21 for molluscum in patients 2+; launch by Sep 2023.
Verrica closes $125M debt financing from OrbiMed; $50M funded, $75M tranched on revenue milestones
$50M borrowed at closing; up to $75M additional available in five tranches subject to YCANTH revenue thresholds.
Verrica FDA approves YCANTH for molluscum; secures up to $125M debt financing
YCANTH (cantharidin 0.7%) topical solution approved for molluscum contagiosum in patients 2+ years; first FDA-approved treatment for the indication.
Verrica reports FY 2022 net loss $24.5M; VP-102 PDUFA set for July 23, 2023
Net loss of $24.5M ($0.72/share) for FY 2022 vs $35.1M ($1.30/share) in FY 2021.
Verrica reports $34.3M cash; updates on VP-102 NDA and VP-315 Phase 2 trial
Preliminary cash and cash equivalents of $34.3M as of Dec 31, 2022, unaudited and subject to change.
Verrica prices $32.5M underwritten offering of common stock and pre-funded warrants
750,000 shares at $6.75 and 4,064,814 pre-funded warrants at $6.7499 per share.
Verrica resubmits NDA for VP-102 (molluscum contagiosum) to FDA
Resubmitted the New Drug Application for VP-102 to the FDA on January 24, 2023.
Verrica Q3 net income $83K; reiterates VP-102 NDA resubmission in Q1 2023
Q3 GAAP net income of $83K ($0.00/sh) vs net loss of $12.8M in Q3 2021; non-GAAP net income $2.9M ($0.07/sh).
Verrica Q2 net loss $10.2M; plans VP-102 NDA resubmission in Q1 2023
Q2 2022 net loss $10.2M ($0.37 GAAP EPS); non-GAAP net loss $8.8M ($0.32/share).
On April 22, 2025, Christopher G. Hayes notified Verrica Pharmaceuticals Inc. (the “ Company ”) that he will resign from his positions as the Company’s Chief Legal Officer, Chief Compliance Officer and Corporate Secretary effective as of April 30, 2025
On March 31, 2025, the Board of Directors (the “ Board ”) of Verrica Pharmaceuticals Inc. (the “ Company ”) appointed Gavin Corcoran to serve as a director of the Company effective immediately.
On November 1, 2024, the Board appointed Dr. Jayson Rieger as the Company’s President, Chief Executive Officer, and as member of the Board and designated him as the Company’s principal executive officer, each effective as of the Effective Date.
On November 1, 2024, Ted White notified the Company that he will resign from his positions as the Company’s President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “ Board ”) effective as of November 5, 2024
On October 2, 2024, Craig Ballaron, a member of the Board of Directors (the “Board ”) of Verrica Pharmaceuticals Inc. (the “ Company ”), notified the Company that he was resigning from the Board and all committees of the Board, effective immediately.
On September 23, 2024, Terence Kohler, Chief Financial Officer of the Company, notified the Company of his resignation from his position, effective October 4, 2024 (the “Separation Date”), to pursue a new business opportunity.
on August 30, 2024, the Company and Joe Bonaccorso, the Company’s former Chief Commercial Officer, entered into a Release Agreement and a Consulting Agreement
On August 21, 2024, Mr. Bonaccorso notified Verrica Pharmaceuticals Inc. (the “Company”) that he will resign from his position as Chief Commercial Officer of the Company, effective August 30, 2024.
On July 6, 2021, Verrica Pharmaceuticals Inc. (the “Company”) notified Brian Davis that his employment as Chief Financial Officer of the Company would terminate, effective as of July 16, 2021.
On July 8, 2021 the board of directors (the “Board”) of the Company appointed Terry Kohler as the Company’s Chief Financial Officer, effective as of July 16, 2021.
Max materiality 0.85 · Median 0.65 · Most common event other_material